Results 181 to 190 of about 1,466,333 (379)
The regulatory effects and applications of TIGIT/CD155 on the tumor microenvironment in HCC
Background The interaction between TIGIT and CD155 compromises immune cell efficacy in tumor targeting, potentially driving hepatocellular carcinoma (HCC) progression through diverse molecular pathways. What Was Done This study investigates the interplay between CD155 and TIGIT in regulating CD8+ T cell function and elucidates its implications in HCC ...
Wenting Li+10 more
wiley +1 more source
Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3) [PDF]
Rainer Riesenberg+3 more
openalex +1 more source
SCF and TSLP expression are known to drive unique immune responses leading to the onset of allergic and inflammatory diseases. Here, we describe the characterization of a novel bsAb, CDX‐622, that targets SCF and TSLP. CDX‐622 inhibits MC functions through SCF starvation and Type 2 inflammatory responses via TSLP inhibition.
Michael B. Murphy+17 more
wiley +1 more source
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
Haitao Pan,1,2 Jiayu Liu,1,2 Wentong Deng,1,2 Jieyu Xing,1,2 Qing Li,1,2 Zhong Wang1,2 1School of Pharmaceutical Sciences, 2Centre for Cellular & Structural Biology, Sun Yat-Sen University, Guangzhou, People’s Republic of China Introduction ...
Pan H+5 more
doaj
Depletion of CCR5-Expressing Cells with Bispecific Antibodies and Chemokine Toxins: A New Strategy in the Treatment of Chronic Inflammatory Diseases and HIV [PDF]
Hilke Brühl+4 more
openalex +1 more source
Summary Developing new therapeutic regimens for relapsed/refractory (R/R) B non‐Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax (VEN) combination in patients with R/R NHL who had received at least one prior anti‐CD20‐containing ...
Charles Herbaux+21 more
wiley +1 more source
Bispecific antibodies (BsAbs) represent a promising strategy for cancer immunotherapy. Challenges in immunotherapy include inefficient early events in the immune response cycle, such as antigen presentation and T cell priming.
Kun Du, He Huang
doaj
The role of blinatumomab in adult acute B lymphoblastic leukaemia
Blinatumomab, a CD19‐directed bispecific T‐cell engager, has become a crucial part of BCP‐ALL therapy in r/r disease, MRD‐positive disease and has recently been implemented into first‐line therapy of BCP‐ALL. This review discusses important clinical trials with a focus on blinatumomab in first‐line therapy of adult BCP‐ALL.
Anne C. Wilke, Nicola Gökbuget
wiley +1 more source
Bispecific Monoclonal Antibodies Mediate Binding of Dengue Virus to Erythrocytes in a Monkey Model of Passive Viremia [PDF]
Chang S. Hahn+4 more
openalex +1 more source